利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

55 条记录 (耗时 0.023 秒)

    TARGETED ANTIVIRAL DRUGS
    4.
    发明公开
    TARGETED ANTIVIRAL DRUGS 审中-公开

    公开(公告)号：US20230173096A1

    公开(公告)日：2023-06-08

    申请号：US17926004

    申请日：2021-05-18

    申请人： NORTHWESTERN UNIVERSITY

    发明人： C. Shad Thaxton ,  Kaylin M. McMahon ,  Stephen E. Henrich

    IPC分类号： A61K47/69 ,  C12N15/113 ,  C07K16/28 ,  A61P31/14

    CPC分类号： A61K47/6917 ,  A61K47/6929 ,  C12N15/1138 ,  C07K16/28 ,  A61P31/14 ,  C12N2310/14

    摘要： Disclosed herein are agents that target cholesterol metabolism (e.g., synthetic nanostructures), pharmaceutical compositions, kits, or methods for treating and/or preventing viral infections. In some embodiments, the agents that target cholesterol metabolism and/or pharmaceutical compositions are delivered to the subject's respiratory system. In some embodiments, the viral infection is caused by a respiratory vims. In some embodiments, the virus is adenovirus (ADV); influenza virus, human bocavims (HBoV); human coronavirus (HCoV); human metapneumo vims (HMPV); human parainfluenza virus (HPIV); human respiratory syncytial vims (HRSV); human rhino vims (HRV); severe acute respiratory syndrome coronavirus (SARS-CoV); and Middle East Respiratory Syndrome coronavirus (MERS-CoV). In some embodiments, the virus is SARS-CoV-2.

    METHODS FOR TARGETED IMAGING WITH SPHERICAL rHDLs
    8.
    发明公开
    METHODS FOR TARGETED IMAGING WITH SPHERICAL rHDLs 审中-公开

    公开(公告)号：US20240307565A1

    公开(公告)日：2024-09-19

    申请号：US18736873

    申请日：2024-06-07

    申请人： Signablok, Inc.

    发明人： Alexander B. Sigalov

    IPC分类号： A61K51/12 ,  A61K47/69

    CPC分类号： A61K51/1224 ,  A61K47/6917

    摘要： A new approach to targeting imaging agents to macrophage-rich sites of interest is disclosed. Compositions of the invention are rHDL and HDL-like liposomal compositions, protein constituents of which, apolipoproteins A-I and/or A-II or fragments thereof are used not only as structural but also as targeting agents. This is achieved by certain controlled chemical or enzymatic modification of apolipoproteins A-I or A-II or fragments thereof. Such modification converts these apolipoproteins to substrates for macrophage scavenger receptors and results in the improvement of contrast agent-(HDL/modified apolipoprotein)-particle association with macrophages and/or absorption (uptake) by macrophages when compared to that of the contrast agent-(HDL/apolipoprotein)-particle constructed with non-modified naturally occurring apo A-I. The compositions can be used for noninvasive specific in vivo molecular detection and localization of macrophage-rich sites of interest using imaging techniques such as computed tomography (CT), gamma-scintigraphy, positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI).

    Spherical rHDLs for targeted imaging
    9.
    发明授权
    Spherical rHDLs for targeted imaging 有权

    公开(公告)号：US12036294B2

    公开(公告)日：2024-07-16

    申请号：US17111371

    申请日：2020-12-03

    申请人： Signablok, Inc.

    发明人： Alexander B Sigalov

    IPC分类号： A61K51/12 ,  A61K47/69

    CPC分类号： A61K51/1224 ,  A61K47/6917

    摘要： A new approach to targeting imaging agents to macrophage-rich sites of interest is disclosed. Compositions of the invention are rHDL and HDL-like liposomal compositions, protein constituents of which, apolipoproteins A-I and/or A-II or fragments thereof are used not only as structural but also as targeting agents. This is achieved by certain controlled chemical or enzymatic modification of apolipoproteins A-I or A-II or fragments thereof. Such modification converts these apolipoproteins to substrates for macrophage scavenger receptors and results in the improvement of contrast agent-(HDL/modified apolipoprotein)-particle association with macrophages and/or absorption (uptake) by macrophages when compared to that of the contrast agent-(HDL/apolipoprotein)-particle constructed with non-modified naturally occurring apo A-I. The compositions can be used for noninvasive specific in vivo molecular detection and localization of macrophage-rich sites of interest using imaging techniques such as computed tomography (CT), gamma-scintigraphy, positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI).